Large changes in urinary pH caused by the concurrent use of alkalinising drugs such as sodium bicarbonate can, in some patients, have a marked effect on the plasma
levels of mexiletine
The effect does not appear to be predictable. The UK manufacturer of mexiletine
recommends that concurrent use should be avoided.